» Articles » PMID: 26867220

Non-Classical Monocytes and Monocyte Chemoattractant Protein-1 (MCP-1) Correlate with Coronary Artery Calcium Progression in Chronically HIV-1 Infected Adults on Stable Antiretroviral Therapy

Abstract

Background: Persistent inflammation and immune activation has been hypothesized to contribute to increased prevalence of subclinical atherosclerosis and cardiovascular disease (CVD) risk in patients with chronic HIV infection. In this study, we examined the correlation of peripheral monocyte subsets and soluble biomarkers of inflammation to coronary artery calcium (CAC) progression, as measured by cardiac computed tomography scan.

Methods: We conducted a longitudinal analysis utilizing baseline data of 78 participants with HIV infection on stable antiretroviral therapy (ART) in the Hawaii Aging with HIV-Cardiovascular study who had available baseline monocyte subset analysis as well as CAC measurement at baseline and at 2-year follow up. Monocyte phenotypes were assessed from cryopreserved blood by flow cytometry and plasma was assayed for soluble biomarkers using antibody-coated beads in a high sensitivity Milliplex Luminex platform. Change in CAC over 2 years was analyzed as the primary outcome variable.

Results: Of all monocyte subsets and biomarkers tested, higher non-classical monocyte percentage (ρ = 0.259, p = 0.022), interleukin (IL)-6 (ρ = 0.311, p = 0.012), and monocyte chemoattractant protein (MCP)-1 (ρ = 0.524, p = <0.001) were significantly correlated to higher 2-year CAC progression in unadjusted Spearman's correlation. Non-classical monocyte percentage (ρ = 0.247, p = 0.039), and MCP-1 (ρ = 0.487, p = <0.001), remained significantly correlated to 2-year CAC progression, while IL-6 was not (ρ = 0.209, p = 0.120) after adjustment for age, hypertension, diabetes mellitus, total/HDL cholesterol ratio, smoking history, and BMI.

Conclusion: The percentage of non-classical monocytes and plasma MCP-1 levels were independently associated with CAC progression and may be related to the progression of atherosclerosis and increased CVD risk associated with chronic HIV infection on stable ART.

Citing Articles

Evaluating immunological and inflammatory changes of treatment-experienced people living with HIV switching from first-line triple cART regimens to DTG/3TC B/F/TAF: the DEBATE trial.

Cossarizza A, Cozzi-Lepri A, Mattioli M, Paolini A, Neroni A, De Biasi S Front Immunol. 2023; 14:1279390.

PMID: 37908359 PMC: 10613634. DOI: 10.3389/fimmu.2023.1279390.


LDL associates with pro-inflammatory monocyte subset differentiation and increases in chemokine receptor profile expression in African Americans.

Gutierrez-Huerta C, Turner B, Claudel S, Farmer N, Islam R, Mitchell V Int J Cardiol. 2022; 358:88-93.

PMID: 35436557 PMC: 9120048. DOI: 10.1016/j.ijcard.2022.04.038.


Plasma CD16 Extracellular Vesicles Associate with Carotid Artery Intima-Media Thickness in HIV Adults on Combination Antiretroviral Therapy.

Marques de Menezes E, Deng X, Liu J, Bowler S, Shikuma C, Stone M mBio. 2022; 13(3):e0300521.

PMID: 35435733 PMC: 9239192. DOI: 10.1128/mbio.03005-21.


Sex modifies the association between HIV and coronary artery disease among older adults in Uganda.

Longenecker C, Bogorodskaya M, Margevicius S, Nazzinda R, Bittencourt M, Erem G J Int AIDS Soc. 2022; 25(1):e25868.

PMID: 34995413 PMC: 8741262. DOI: 10.1002/jia2.25868.


Nature versus Number: Monocytes in Cardiovascular Disease.

Williams H, Mack C, Li S, Fletcher J, Medbury H Int J Mol Sci. 2021; 22(17).

PMID: 34502027 PMC: 8430468. DOI: 10.3390/ijms22179119.


References
1.
Dawson T, Kuziel W, Osahar T, Maeda N . Absence of CC chemokine receptor-2 reduces atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis. 1999; 143(1):205-11. DOI: 10.1016/s0021-9150(98)00318-9. View

2.
Aiello R, Bourassa P, Lindsey S, Weng W, Natoli E, Rollins B . Monocyte chemoattractant protein-1 accelerates atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 1999; 19(6):1518-25. DOI: 10.1161/01.atv.19.6.1518. View

3.
. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25):3143-421. View

4.
Raggi P, Callister T, Shaw L . Progression of coronary artery calcium and risk of first myocardial infarction in patients receiving cholesterol-lowering therapy. Arterioscler Thromb Vasc Biol. 2004; 24(7):1272-7. DOI: 10.1161/01.ATV.0000127024.40516.ef. View

5.
Carr J, Nelson J, Wong N, McNitt-Gray M, Arad Y, Jacobs Jr D . Calcified coronary artery plaque measurement with cardiac CT in population-based studies: standardized protocol of Multi-Ethnic Study of Atherosclerosis (MESA) and Coronary Artery Risk Development in Young Adults (CARDIA) study. Radiology. 2004; 234(1):35-43. DOI: 10.1148/radiol.2341040439. View